

RESEARCH ARTICLE

Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo

Alexa Pichet Binette¹  | Angela Mammana² | Laura Wisse³ | Marcello Rossi² |
 Olof Strandberg¹ | Ruben Smith^{1,4} | Niklas Mattsson-Carlsson^{1,5,6} |
 Shorena Janelidze¹ | Sebastian Palmqvist^{1,4} | ADNI | Alice Ticca⁷ |
 Erik Stomrud^{1,4} | Piero Parchi^{2,7} | Oskar Hansson^{1,4}

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden²IRCCS, Istituto delle Scienze Neurologiche di Bologna (ISNB), Bologna, Italy³Diagnostic Radiology Unit, Department of Clinical Sciences Lund, Lund University, Lund, Sweden⁴Memory Clinic, Skåne University Hospital, Malmö, Sweden⁵Department of Neurology, Skåne University Hospital, Malmö, Sweden⁶Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden⁷Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

Correspondence

Alexa Pichet Binette, Clinical Memory Research Unit, BMC, Lund University, Sölvegatan 19, 221 84 Lund, Sweden.
 Email: alexa.pichet_binette@med.lu.se

Piero Parchi, IRCCS Istituto delle Scienze Neurologiche, Ospedale Bellaria, Via Altura 1/8, Bologna 40139, Italy.
 Email: piero.parchi@unibo.it

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Funding information

National Institute on Aging; Alzheimer's Association; GHR Foundation, Swedish Research Council, Grant/Award Numbers: 2022-00775, 2021-02219, 2018-02052; ERA

Abstract

INTRODUCTION: We examined the relations of misfolded alpha synuclein (α -synuclein) with Alzheimer's disease (AD) biomarkers in two large independent cohorts.

METHODS: We included Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Two (BioFINDER-2) and Alzheimer's Disease Neuroimaging Initiative (ADNI) participants ($n = 2315$, cognitively unimpaired, mild cognitive impairment, AD dementia) who had cross-sectional cerebrospinal fluid (CSF) α -synuclein measurement from seed-amplification assay as well as cross-sectional and longitudinal amyloid beta ($A\beta$) and tau levels (measured in CSF and/or by positron emission tomography). All analyses were adjusted for age, sex, and cognitive status.

RESULTS: Across cohorts, the main biomarker associated with α -synuclein positivity at baseline was higher levels of $A\beta$ pathology (all p values ≤ 0.02), but not tau. Looking at longitudinal measures of AD biomarkers, α -synuclein –positive participants had a statistically significant faster increase of $A\beta$ load, although of modest magnitude (1.11 Centiloid/year, $p = 0.02$), compared to α -synuclein –negative participants in BioFINDER-2 but not in ADNI.

Alexa Pichet Binette and Angela Mammana contributed equally to this work as first authors.

Oskar Hansson and Piero Parchi contributed equally to this work as senior authors.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Author(s). *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

PerMed, Grant/Award Number: ERAPERMED2021-184; Knut and Alice Wallenberg foundation, Grant/Award Number: 2022-0231; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation, Grant/Award Numbers: AF-980907, AF-980832, AF-993465, AF-939981; Swedish Brain Foundation; Parkinson foundation of Sweden, Grant/Award Number: 1412/22; Cure Alzheimer's fund, Grant/Award Number: WASP/DDLS22-066; EU Joint Programme Neurodegenerative Diseases, Grant/Award Number: 2019-03401; Rönström Family Foundation, Grant/Award Number: FRS-0003; Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse; Skåne University Hospital Foundation, Grant/Award Number: 2020-O000028; Regionalt Forskningsstöd, Grant/Award Number: 2022-1259; Swedish federal government under the ALF agreement; Italian Ministero della Salute; Alzheimer's Disease Neuroimaging Initiative; National Institutes of Health; National Institute of Biomedical Imaging and Bioengineering; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; BristolMyers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-LaRoche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; MesoScale Diagnostics; LLC; NeuroRxResearch; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Takeda Pharmaceutical Company; and Transition Therapeutics; Fonds de Recherche en Santé Québec, Grant/Award Number: 298314; H2020 European Research Council, Grant/Award Number: ADG-101096455

DISCUSSION: We showed associations between concurrent misfolded α -synuclein and $A\beta$ levels, providing in vivo evidence of links between these two molecular disease pathways in humans.

KEYWORDS

amyloid beta, co-pathology, Lewy body, neurodegenerative diseases, seed-amplification assay, tau

Highlights:

- Amyloid beta ($A\beta$), but not tau, was associated with alpha-synuclein (α -synuclein) positivity.
- Such association was consistent across two cohorts, beyond the effect of age, sex, and cognitive status.
- α -synuclein-positive participants had a small, statistically significant faster increase in $A\beta$ positron emission tomography levels in one of the two cohorts.

1 | INTRODUCTION

Aggregates of misfolded alpha-synuclein (α -synuclein) proteins result in the formation of Lewy bodies and Lewy neurites in the brain.¹ Lewy bodies and neurites are the core pathology of neuronal α -synuclein disease (i.e., Parkinson's disease [PD] and dementia with Lewy bodies [DLB]).² They co-occur frequently with Alzheimer's disease (AD) pathology in brain tissue from patients with the clinical diagnosis of either AD dementia^{3–5} or neuronal α -synuclein disease.^{6,7} Further, many experimental and animal models suggest potential synergistic interaction between α -synuclein and AD pathology, that is, amyloid beta ($A\beta$) or tau, although such interactions have yet to be investigated in humans in vivo.^{8,9} Until recently, biomarkers that could measure α -synuclein pathology in vivo with high accuracy and

sensitivity were lacking. However, with recent improvement in seed-amplification assays (SAAs), it is now possible to indirectly detect misfolded α -synuclein aggregates in cerebrospinal fluid (CSF), providing a biomarker specific to Lewy body disease.¹⁰ The availability of such novel assays thus enables us to better understand the clinicopathological relations between α -synuclein and AD pathologies. We have shown previously that cognitively unimpaired participants who had both AD and neuronal α -synuclein pathologies had faster memory and executive function decline compared to those with AD pathology alone or neuronal α -synuclein pathology alone.¹¹ Here, we aimed to examine the associations between misfolded α -synuclein aggregates measured with SAA and concomitant $A\beta$ and tau levels cross-sectionally, as well as with accumulation of $A\beta$ and tau levels over time in two large cohorts covering the AD spectrum.

2 | MATERIALS AND METHODS

2.1 | Participants—BioFINDER-2 cohort

We included all participants from the ongoing prospective Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Two (BioFINDER-2) cohort (NCT03174938) who had CSF α -SAA measurement, as well as measures of $A\beta$ and tau available at baseline; who were > 50 years old; and were cognitively unimpaired (CU), had mild cognitive impairment (MCI), or AD dementia.

Analyses focused on positron emission tomography (PET) were restricted to CU and participants with MCI, given that as per the cohort protocol, patients with dementia undergo tau PET but not $A\beta$ PET, for a total of 1074 individuals. Analyses focused on CSF measures of AD biomarkers included the full spectrum of AD, for a total of 1273 individuals. The main inclusion and exclusion criteria are described in supporting information and in Palmqvist et al.¹² All CU participants had a Mini-Mental State Examination (MMSE) between 27 and 30 or 26 and 30 depending on age. MCI diagnosis was established as performance below 1.5 standard deviation of normative score on at least one cognitive domain from an extensive neuropsychological battery and all had a MMSE between 24 and 30. Diagnosis of AD fulfilled the Diagnostic and Statistical Manual of Mental Disorders Fifth edition criteria for mild or major neurocognitive disorder due to AD, as well as criteria for $A\beta$ positivity, as per the National Institute on Aging–Alzheimer's Association and the International Working Group criteria. Participants with non-AD neurodegenerative diseases, such as Lewy body diseases, were not included in the main analyses, to match sample selection with the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. However, in a complementary analysis to compare associations in the AD continuum to patients with Parkinsonian disorders, we conducted logistic regressions in a subpopulation of BioFINDER-2 with such disorders ($n = 177$; 7 corticobasal syndrome, 48 DLB, 15 multiple system atrophy, 75 PD, and 32 progressive supranuclear palsy). Overall, α -synuclein status, and $A\beta$ and tau biomarkers (either from PET or CSF) were all taken from the baseline visit. $A\beta$ and tau PET were also available longitudinally, all prospective to the baseline visit. The study was approved by the regional ethics committee in Lund, Sweden. All data for the current study were acquired between January 2017 and May 2023.

2.2 | Participants—ADNI cohort

We selected ADNI participants who had a measure of CSF α -synuclein based on SAA, as well as at least one $A\beta$ PET scan available. ADNI is a multi-site study launched in 2003 as a public–private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. For up-to-date information, see www.adni-info.org. The last lumbar puncture available was selected for the CSF α -synuclein assay by the ADNI investigators. We then selected the

RESEARCH IN CONTEXT

- 1. Systematic review:** We reviewed the literature on misfolded alpha-synuclein (α -synuclein) aggregates and Alzheimer's disease (AD) pathology in living humans using traditional sources like PubMed. This is a new area given the only recent availability of cerebrospinal fluid (CSF) seed-amplification assays for α -synuclein aggregates. The relevant studies are appropriately cited.
- 2. Interpretation:** We found co-occurrence of α -synuclein positivity and elevated amyloid beta ($A\beta$) levels, but not tau (both measured either in CSF or by positron emission tomography), across two large cohorts spanning the AD spectrum. Our results are overall consistent with previous *post mortem* studies.
- 3. Future directions:** We provide novel evidence for in vivo associations between $A\beta$ and α -synuclein in the AD continuum. Future studies should investigate if there are potential additive or synergistic effects of abnormal α -synuclein and $A\beta$ accumulation in the brain and the molecular mechanisms that are at play.

$A\beta$ PET closest to the α -synuclein measure for cross-sectional analysis, allowing a maximum 2-year interval between CSF α -synuclein and PET (average time difference between measures of -0.02 ± 0.29 year) to maximize the sample size (see Figure S1 in supporting information for a flow chart of ADNI participants selection). The overlap of participants with an α -synuclein assay and tau PET done within 2 years was less than one third of the sample, and thus tau PET was not included in the ADNI analyses. All data were collected between December 2008 and December 2022. Overall, we included a sample of 1242 participants, composed of CU individuals, and individuals with MCI and AD dementia. CU participants had a Clinical Dementia Rating score of 0 and participants with MCI and AD were diagnosed according to standard criteria.¹³

2.3 | α -synuclein

α -synuclein SAAs in CSF, which detect if α -synuclein aggregates are present or not, were used in both cohorts. The output is a binary variable indicating if the CSF sample is positive or negative for aggregates. α -synuclein seeding activity measured by SAAs is expressed in relative fluorescence units (RFUs). The assay's positivity or negativity, indicating the presence or absence of Lewy body pathology, is based on the number of replicates showing fluorescent curves exceeding a given threshold, which is calculated based on the background fluorescent signal recorded in negative controls.

The α -synuclein SAA testing of the BioFINDER-2 cohort was performed by the Neuropathology Laboratory at IRCCS-ISNB (Italy) with

a validated method initially developed by Byron Caughey's lab (United States).¹⁴ For this analysis, each CSF sample was tested in quadruplicate. CSF samples were classified as positive if at least three replicates (maximum fluorescence signal above 30% of the median iMax of the positive controls) and negative if none of the replicates exceeded the threshold. Samples showing one or two positive replicates were repeated three times and classified as positive if at least 4 of the total 12 replicates exceeded the threshold. The protocol is described in more detail in supporting information and in recent publications.^{11,15}

The α -syn SAA testing in ADNI was conducted by Amprion Clinical Laboratory (United States; CLIA ID No. 05D2209417; CAP No. 8168002) with a validated method. For the analysis, each CSF sample was tested in triplicate. CSF samples were classified as positive if all three replicates showed an aggregation profile consistent with Type 1 seeds (maximum fluorescence signal, iMAX, > 45,000 RFUs) observed in PD and DLB or "not detected" if no or only one replicate exceeded the threshold.¹⁶ The detailed protocol, provided by Amprion, is available in the ADNI database (Amprion synuclein seeding assay). In ADNI, 1252 participants had an A β PET within 2 years of the α -synuclein assay out of a total of 1641 participants. We further excluded 10 participants who had either a result that was "indeterminate" (i.e., determination could not be made after the sample was tested twice) or detected Type 2 seeds, which are seen in multiple system atrophy, for the final sample of 1242 participants mentioned above. Outcomes were thus consistent in both cohorts, that is, only negative samples and those with Type 1 seeds seen in PD and Lewy body dementia (positive samples) were retained.

In both cohorts, only cross-sectional measurements of α -synuclein were available and assays were performed blinded to diagnosis and demographics. Overall the two methods have shown similar accuracy in neuropathologically verified cohorts^{17,18} and to distinguish between early PD patients and controls.¹⁹ An overview of the critical variables in the two SAAs in BioFINDER-2 and ADNI is provided in Table S1 in supporting information.

2.4 | PET imaging and processing

In BioFINDER-2, A β and tau PET images were acquired on digital GE Discovery MI scanners. Acquisition for A β PET was done 90 to 110 minutes post injection of \approx 185 MBq [18F]Flutemetamol and 70 to 90 minutes post injection of \approx 370 MBq [18F]RO948 for tau PET. Images were processed according to our pipeline described previously.²⁰ Briefly, PET images were attenuation corrected, motion corrected, summed, and registered to the closest T1-weighted MRI image processed through the longitudinal pipeline of FreeSurfer version 6.0. Structural T1-weighted images were acquired from a magnetization-prepared rapid gradient echo (MPRAGE) sequence with 1 mm isotropic voxels on a Siemens 3T MAGNETOM Prisma scanner. Standardized uptake value ratio (SUVR) images were created using the whole cerebellum as reference region for [18F]Flutemetamol²¹ and the inferior cerebellar gray matter for [18F]RO948. For A β PET, the main region of interest was the average SUVR from a global neocortical region

including prefrontal, lateral temporal, parietal, anterior cingulate, and posterior cingulate/precuneus (same regions as in ADNI; scans > 1.03 SUVR were considered A β PET positive²¹). Centiloids were also calculated using calibrating images from the Global Alzheimer's Association Interactive Network website. For tau PET, the main region of interest was the average SUVR temporal composite region of the entorhinal cortex, amygdala, parahippocampal gyrus, inferior temporal, and middle temporal gyri.²² Based on a previously established cutoff of 1.36 SUVR in this temporal meta-region of interest (ROI),²⁰ 28% of the sample would be tau PET positive. On average, 47% of the participants also had longitudinal PET data available ($n = 567$ for A β and $n = 596$ for tau), with two to four follow-up scans. The average follow-up time was 2.6 ± 1.0 years. In complementary analyses, we also performed the main analyses in BioFINDER-2 using regional A β or tau SUVR from all neocortical regions (as well as the amygdala for tau).

In ADNI, A β PET acquisition included two tracers ([18F]florbetapir with acquisition 50 to 70 minutes post injection and [18F]florbetaben with acquisition 90 to 110 minutes post injection). Briefly, frames were realigned, averaged, resliced to a common voxel size, smoothed to 8 mm³, and registered to the closest T1 MPRAGE image that had been processed through FreeSurfer 7.1. Whole cerebellum was used as the reference region to generate SUVR and the ROI was the global neocortical region as described above. To determine A β PET positivity, a cutoff of 1.11 SUVR for florbetapir and 1.08 SUVR for florbetaben were used, defined by the ADNI PET Core. Given that two tracers were used, our main measure of interest was the Centiloid value, taken from the ADNI database and based on the most updated methods (see Amyloid PET Processing Methods version 2; revised June 29, 2023). Thirty-eight percent of the participants ($n = 473$) also had longitudinal A β PET scans prospective to the time point at which the α -synuclein status was determined (average follow-up time of 3.74 ± 2.22 years, 2 to 6 scans). In the main analyses for longitudinal A β PET in ADNI, we included these scans prospective to α -synuclein status to be in line with the longitudinal BioFINDER-2 data (in which all longitudinal data is prospective from the baseline visit). In a sensitivity analysis, we extended our selection to PET scans both retrospective or prospective to the α -synuclein measurement, to maximize the length of the A β PET trajectories and ensure that results were consistent across different data selection. Cross-sectional analyses were conducted when merging the two cohorts (using Centiloids) and were validated separately in each cohort.

2.5 | CSF biomarkers of A β and phosphorylated tau

We also investigated the cross-sectional relations between α -synuclein and AD pathology measured with CSF. In both cohorts, A β 42 and phosphorylated tau181 (p-tau181) levels were measured using the Elecsys immunoassays in pg/mL.²³ Lower levels of A β 42 in CSF correspond to higher A β pathology and higher levels of p-tau181 in CSF correspond to higher tau pathology. Results related to CSF A β were inverted to be easier to interpret and to follow the same direction as p-tau181 and PET results. In BioFINDER-2, CSF biomarkers were

available across the full spectrum of the disease ($n = 1273$ including CU, MCI, and AD). Additionally, in BioFINDER-2, A β 40 was also available measured with the same assay, which allowed us to derive the A β 42/40 ratio, which is preferred over A β 42 alone. We used this ratio to determine A β positivity in BioFINDER-2, in which individuals with a value > 0.08 were considered A β positive.²⁴ In CSF analyses performed in BioFINDER-2 only, we used A β 42/40 as our measure of interest. In analyses merging both BioFINDER-2 and ADNI, A β 42 alone was used. In ADNI, concentrations of A β 42 and p-tau181 were available for 70% of the sample who had A β PET ($n = 864/1242$; all details in the UPENN CSF Biomarkers Roche Elecsys Methods in LONI). For A β 42, in ADNI, values above the upper level of detection (1700 pg/mL) were imputed at 1700 ($n = 150$ out of 864), while in BioFINDER-2, for samples above the detection limit ($n = 436$ out of 1273), A β 42 values were extrapolated from the standard curve. As done with PET, cross-sectional analyses were conducted when merging the two cohorts and were validated separately in each cohort. The analyses in the separate individual cohort used the full dataset available in each cohort. To merge the CSF concentrations across the two cohorts, harmonization of A β 42 needed to be performed, using an approach previously described to harmonize such values between ADNI and BioFINDER data.²⁵ Importantly, in the merged dataset, participants with A β 42 values equal to or higher than the highest detection limit were removed to ensure harmonization across values in a similar range (total $n = 1550$ in the merged dataset with CSF). We calculated the percent mean difference between the two cohorts and multiplied the value for a given cohort by this coefficient, if the mean difference between cohorts was significant. For A β 42, the ADNI values were on average 8.51% (95% confidence interval [CI]: 8.07–8.96, p value < 0.001) lower than in BioFINDER-2 (ADNI average: 865.66 [95% CI: 839.05–892.27], BioFINDER-2 average: 1026.62 [95% CI: 1004.28–1048.96]), likely because BioFINDER-2, but not ADNI, uses LoBind tubes for collection and storage of CSF, which results in higher A β 42 levels.^{26,27} As such, A β 42 concentrations in ADNI were multiplied by 1.085 to reach the harmonized A β 42 concentrations. There was no significant difference in the mean concentrations of p-tau181, with a percent mean difference of 1.40% (95% CI: 1.40–1.42, p value = 0.34), and thus no harmonization needed to be performed (ADNI average = 27.95 [26.81, 29.10]; BioFINDER-2 average = 27.18 [26.07, 28.28]). Longitudinal, prospective CSF measures after the α -synuclein measurement were not available in either cohort.

2.6 | Statistical analysis

Characteristics between α -synuclein-positive and -negative participants were compared using t tests for continuous variables and chi-square for categorical variables. We used logistic regressions to investigate cross-sectional associations between α -synuclein status as outcome (positive or negative) and measures of AD pathology (using PET or CSF) as predictors. The main analysis investigating the effect of A β PET was done by grouping both cohorts using Centiloids. Similarly, the main analysis investigating the effect of CSF A β 42 and p-tau181

was done by grouping both cohorts. Analyses were also conducted in each individual cohort. In BioFINDER-2 alone, in which both A β -PET and tau-PET were analyzed, global A β and temporal meta-ROI tau-PET SUVR were added as independent variables in the same model. In ADNI alone, A β Centiloids was the main independent variable. All models were adjusted for age, sex, and cognitive status (cognitively unimpaired or impaired) by adding these variables as additional predictors in the logistic regression, to account for their impact on the different proteinopathies. The models combining both BioFINDER-2 and ADNI were also further adjusted for the cohort. In sensitivity analyses, we also further adjusted for apolipoprotein E (APOE) ϵ 4 genotype (carriers [having at least one ϵ 4 allele] vs. non-carriers), given its strong link to A β . We also repeated the same models with fewer covariates to evaluate if results remained the same: we fitted the same logistic regressions when (1) adjusting only for age and sex or (2) having only AD biomarkers as independent variables and no covariates. Across all models, multicollinearity was low (with variance inflation factors of maximum 1.7) and no outlier influenced the results.

We also wanted to better understand whether the presence of α -synuclein influenced the trajectories of AD biomarkers over time, to complement associations detected with cross-sectional data only. To evaluate the effect of α -synuclein status on longitudinal AD biomarkers, we fitted separate linear mixed effect models with longitudinal PET measures (global A β SUVR and temporal meta-ROI tau-PET SUVR in BioFINDER-2 [to use the raw values], A β Centiloids in ADNI) as outcome, including random slopes and intercepts with restricted maximum likelihood from lme4 v1.1-35.1. The α -synuclein status \times time was the main variable of interest and all models included age, sex, and cognitive status as covariates. Time was operationalized as years from the α -synuclein measurement, where α -synuclein measurement was considered $t = 0$. All covariates were taken from $t = 0$, only PET measurements were time varying. p values ≤ 0.05 were considered significant. Analyses were performed in R v4.3.2 and plots were generated with ggplot2 v3.4.4.

3 | RESULTS

3.1 | Demographics and α -synuclein positivity

We included 1074 participants from BioFINDER-2 and 1242 participants from ADNI (Table 1), all of whom had CSF α -synuclein status and A β PET available. In BioFINDER-2, 10% of the cohort was α -synuclein positive, compared to 20% in ADNI. Similarly, the proportion of A β -positive participants was slightly higher in ADNI: 52% compared to 41% in BioFINDER-2. In this sample with A β PET, there were no participants with AD dementia in BioFINDER-2, whereas these participants constituted 21% of the ADNI sample. ADNI participants were, on average, almost 5 years older than BioFINDER-2 participants (74.0 vs. 69.6 years old). The two cohorts were balanced in terms of sex. The breakdown of participants by α -synuclein status in each cohort is also provided in Tables S2–S3 in supporting information. The characteristics of participants in the BioFINDER-2 and ADNI who had CSF measures

TABLE 1 Demographics.

	BioFINDER-2 (n = 1074)	ADNI (n = 1242)
Age (years)	69.6 ± 9.9	74.0 ± 7.6
Sex F n (%F)	563 (52%)	607 (49%)
Education (years) ¹	12.8 ± 3.8	16.4 ± 2.5
MMSE	28.3 ± 1.7	27.2 ± 3.4
α-synuclein status n positive (% positive)	112 (10%)	252 (20%)
APOE ε4 carriers n (%) ²	466 (50%)	525 (44%)
Cognitive status	732: 342: 0	476: 508: 257
Unimpaired: MCI: AD dementia (%)	(68: 32: 0%)	(38: 41: 21%)
Aβ status n positive (% positive)	439 (41%)	640 (52%)

Note: Data are presented as mean ± standard deviation unless specified otherwise. α-synuclein status was determined using seed assay amplification in CSF. Aβ status was determined based on CSF Aβ42/40 ratio in BioFINDER-2 and on Aβ PET in ADNI.

Abbreviations: Aβ, amyloid beta; AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; APOE, apolipoprotein E; BioFINDER-2, Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Two; F, female; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; PET, positron emission tomography; ROI, region of interest; SUVR, standardized uptake value ratio.

¹Missing for 17 participants in BioFINDER-2 and 49 in ADNI.

²Missing for 143 participants in BioFINDER-2 and 49 in ADNI.

of AD pathology was highly similar to those who underwent PET, with the exception that it included patients with AD dementia in BioFINDER (Table S4 in supporting information).

3.2 | Cross-sectional associations between α-synuclein and AD biomarkers

In the whole sample combining BioFINDER-2 and ADNI, the variables associated with α-synuclein positivity were Aβ, age, male sex, and cognitive impairment. The odds ratio ranged from 1.24 (95% CI: 1.10–1.39) for Aβ PET (Figure 1A) to 1.39 (95% CI: 1.20–1.62) for CSF Aβ42 (Figure 1B). Covariates included in the same model (age, sex, cognitive impairment) were all significant, as shown in Figure 1. The area under the curve (AUC) was 0.69 for the model with PET and 0.66 for the model with CSF biomarkers. All statistical details are reported in Table S5 in supporting information. Further including APOE ε4 genotype as a covariate did not change the results in the models based on PET or CSF AD biomarkers (Table S5).

Centiloids Aβ PET and CSF Aβ42 levels by α-synuclein status in each cohort are also displayed in Figure 2 for visualization purposes. Across cohorts and Aβ measures, α-synuclein-positive participants consistently had higher Aβ burden, with effect sizes ranging between 0.37 and 40, suggesting a small effect.

Logistic regressions were also tested in each cohort separately, using measures of AD pathology from PET and CSF, which all yielded




FIGURE 1 Odds ratio from logistic regressions assessing α-synuclein positivity. Odds ratio (95% CI) from logistic regression assessing α-synuclein status as outcome are reported. All listed variables were included as independent variables simultaneously in the same model. Main predictors were based on PET measures of AD pathology (A) or CSF measures (B). Logistic regressions were conducted in the merged cohorts, in BioFINDER-2 alone or ADNI alone. α-synuclein, alpha synuclein; Aβ, amyloid beta; AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; BioFINDER-2, Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Two; CI, confidence interval; CSF, cerebrospinal fluid; PET, positron emission tomography.

consistent results from models based on the merged cohorts. Results are displayed in Figure 1 and the statistical details of all models are reported in Table S6 in supporting information. In all models based on CSF measures of AD, Aβ42 (odds ratio of 1.28 [95% CI: 1.05–1.60] in BioFINDER-2 and 1.44 [95% CI: 1.23–1.69] in ADNI) but not p-tau181 was significantly associated with α-synuclein positivity, beyond the effect of age, sex, and cognitive status. The AUC was 0.72 in BioFINDER-2 and 0.64 in ADNI. Results were similar in models based on PET measures of AD. In ADNI, greater Centiloids Aβ was associated with being α-synuclein positive (odds ratio: 1.30 [95% CI: 1.13–1.50]). In BioFINDER-2, logistic regression models included both Aβ- and tau PET as independent variables in the same model, along with age, sex, and cognitive status. Tau PET levels were not significantly associated with α-synuclein status. The effect of Aβ PET was not significant




FIGURE 2 Levels of A β PET and CSF A β 42 by α -synuclein status. Levels of A β Centiloids (A) in BioFINDER-2 and in ADNI as well as CSF A β 42 after harmonization (B) in α -synuclein-negative and -positive participants. Effect size (95% confidence interval) between the groups is reported on top of each graph. α -synuclein, alpha synuclein; A β , amyloid beta; AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; BioFINDER-2, Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Two; CSF, cerebrospinal fluid; PET, positron emission tomography.

beyond cognitive impairment in this sample (odds ratio 1.14, 95% CI: 0.91–1.44, $p = 0.25$ [Figure 1A, Table S6] vs. 1.27, 95% CI: 1.01–1.58, $p = 0.04$ when cognitive status is not included as covariate). The AUC was 0.70 in BioFINDER-2 and 0.62 in ADNI. Repeating the same analyses using regional SUVR, there were no individual regions where PET uptake was associated with α -synuclein positivity (all $p_{FDR} > 0.05$). In BioFINDER-2 the discrepancy in the results between the PET and CSF samples is likely explained by the difference in sample size and participants, given that patients with AD dementia do not undergo A β PET. Results across each cohort and the merged cohorts were also highly consistent when repeating logistic regression without any covariates or when only including age and sex (Table S7 in supporting information). Across all analyses, a higher A β load was consistently associated with α -synuclein positivity, whereas tau measures were not significant. The odds ratio of A β was also slightly higher in the models without or with fewer covariates compared to the main models. Results were different in the BioFINDER-2 subpopulation with Parkinsonian disorders, in which two thirds were α -synuclein positive ($n = 118/177$). In this group A β or tau proteinopathies were not associated with α -synuclein status (Table S8 in supporting information).

3.3 | Associations between α -synuclein and longitudinal AD biomarkers

Next, we investigated whether the α -synuclein groups differed in terms of accumulation of AD pathology over time. In BioFINDER-2, the α -synuclein-positive participants had a statistically significant, albeit small, faster increase in A β PET levels compared to the α -synuclein-negative group (α -synuclein status \times time standardized $\beta = 0.037$, standard error [SE] = 0.014, $p = 0.01$; Figure 3A, statistical details in Table S9 in supporting information). Given that we found that α -synuclein-positive participants had a higher prevalence of A β positivity, we further adjusted the linear mixed effect model for the A β status at baseline (based on CSF A β 42/40), to ensure that the significant accumulation A β pathology was not mainly driven by a high proportion of A β positivity in the α -synuclein-positive group. The interaction between α -synuclein status and time remained similar (standardized $\beta = 0.034$, SE = 0.014, $p = 0.02$), suggesting an effect of α -synuclein on change in A β PET SUVR beyond the fact that α -synuclein-positive participants have higher A β load. However, when investigating such association only in A β -negative participants or only in A β -positive participants, there was no difference in increase of A β PET levels between the two α -synuclein groups (all statistical results in Table S10 in supporting information). To better contextualize the results, we calculated the effects using A β Centiloids: the α -synuclein-positive participants accumulated 1.11 (SE = 0.44) Centiloid more per year than the α -synuclein-negative group. In the same group of participants, there was no apparent difference in longitudinal tau-PET trajectories between the α -synuclein groups (α -synuclein status \times time standardized $\beta = 0.020$, SE = 0.031, $p = 0.51$; Figure 3B, all statistical details in Table S9). Repeating the same analyses using regional SUVR, in line with the widespread deposition of A β , there were 15 individual regions where A β SUVR accumulation was faster in the α -synuclein positive group compared to the negative group (Figure S2 in supporting information, all $p_{FDR} \leq 0.05$). No individual region was significant with longitudinal tau PET. In ADNI, there was no difference between the two α -synuclein groups on their longitudinal accumulation of A β levels prospectively to the α -synuclein measurement (α -synuclein status \times time standardized $\beta = -0.030$, SE = 0.031, $p = 0.33$, Figure 3C, Table S9). Results were also unchanged if we included both retrospective and prospective longitudinal A β PET with respect to the α -synuclein measurement in ADNI (Figure S3 in supporting information).

4 | DISCUSSION

In two independent and large cohorts covering the AD continuum, we found that α -synuclein positivity was associated with elevated A β pathology, but not tau in cross-sectional analyses. Using longitudinal measures of AD biomarkers, we found a small statistically significant faster increase of A β pathology in α -synuclein-positive participants in one cohort only. The cross-sectional results support the abundant literature suggesting frequent co-occurrence of AD pathology and neuronal α -synuclein pathology based on *post mortem* brain tissue,




FIGURE 3 Effect of α -synuclein status on longitudinal A β - and tau PET. Linear mixed effect models investigating the effect of α -synuclein status on longitudinal global neocortical A β SUVR ($n = 567$) (A) and temporal tau PET SUVR ($n = 596$) (B) in BioFINDER-2, and A β Centiloids in ADNI ($n = 473$) (C). Linear mixed effect models with random slope and intercept were fitted, including age and sex as covariates. Standardized beta coefficient (standard error) and p value of α -synuclein status \times time is reported on each graph. Negative/positive indicates CSF α -synuclein status. α -synuclein, alpha synuclein; A β , amyloid beta; AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; BioFINDER-2, Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Two; CSF, cerebrospinal fluid; PET, positron emission tomography; SUVR, standardized uptake value ratio.

reported in patients with AD dementia as well as in patients with neuronal α -synuclein disease (aka Lewy body disease).^{28,29}

Associations between neuronal α -synuclein pathology and tau pathology are also commonly reported in *post mortem* tissue and are not unique to A β pathology. Still, we should note that in some cohorts, correlations were seen only between α -synuclein and A β and not with tau.⁴ Given that *in vivo* A β often starts to deposit years before neocortical tau pathology in the AD pathophysiological cascade, it is perhaps not surprising that we found greater co-occurrence of α -synuclein and A β compared to tau along the AD spectrum, in participants ranging from CU older adults to patients with AD dementia. Such results are also in line with a recent study in ADNI only where

no relations were found between p-tau and α -synuclein positivity.¹⁶ Earlier reports observed that neuronal α -synuclein pathology was also frequent in brains of patients with familial AD, all of whom had mutations causing overproduction of A β ,^{30,31} potentially further linking A β proteinopathy to the development of concomitant α -synuclein aggregates.

It has been proposed that the presence of widespread, pathological accumulation of A β might act as a facilitator or catalyzer for the subsequent aggregation of other proteinopathies and thus induce accumulation of misfolded α -synuclein, as well as tau neurofibrillary tangles (see Spires-Jones et al. and Kotzbauer et al. for reviews).^{32,33} In AD, the amygdala and entorhinal cortex are the most common

regions where neuronal α -synuclein pathology is found, which are the same regions prone to early tau aggregates. This pattern contrasts with α -synuclein pathology in classical neuronal α -synuclein disease (PD and DLB), where a more widespread deposition is found across subcortical areas such as the brainstem, hypothalamus, and basal forebrain.^{7,33} In the context of AD, we thus speculate that potentially similar mechanisms might explain aggregation of tau and α -synuclein in the presence of widespread A β . We do not exclude additive or perhaps synergistic effects that might also occur between α -synuclein and tau in vivo in humans, which have been reported in several experimental animal models,^{8,9} but we could not detect any significant associations between these two pathologies in the current study. One explanation for the lack of association with tau pathology might be the generally low tau burden in patients with AD and Lewy body pathologies. Evidence indicates that the presence of co-pathologies lowers the threshold for meeting clinical criteria for a diagnosis of dementia. Therefore, the association between α -synuclein and A β pathology leads to an earlier presentation of symptoms than in patients with pure AD and can explain the lower tau burden. In other words, the possible interaction between α -synuclein and tau pathology, which has been suggested in experimental studies, might be more difficult to document in vivo because of its later occurrence in the disease course compared to A β and α -synuclein interaction. Age and cognitive status are also other important factors in the presence of concomitant pathologies. We also found that older age and having cognitive impairment were both associated with greater odds of being α -synuclein positive across cohorts, to a similar or greater magnitude than A β . It is likely that both AD-dependent and independent mechanisms exert their effects on α -synuclein pathology in aging and neurodegenerative diseases.

To better elucidate the relations among all pathologies, longitudinal α -synuclein measurements will be crucial and are not yet available. Longitudinal measurements of α -synuclein in the future will allow us to further clarify the timing between the different pathological changes and how they relate to one another. In one cohort we found a small faster increase of A β over time in the α -synuclein-positive group, but to start to understand if one pathology might "drive" or "trigger" the other, the reverse association will need to be tested, that is, assessing α -synuclein over time in A β -positive and -negative participants. As such, we do not imply directionality or causality from the present results, and potential bidirectional effects are likely to be at play.^{9,34} The longitudinal effect reported here was found in BioFINDER-2 and not in ADNI and will also need to be investigated further in other cohorts. Still, it is also important to note some differences between the two cohorts, which might explain in part the discrepant result. We used stringent criteria to define α -synuclein positivity in BioFINDER-2, which might result in more participants with focal pathology in ADNI compared to BioFINDER-2. Such participants would be less likely to show an interaction with A β because the Lewy body pathology has not reached the cerebral cortex. Overall, there were up to 10% more α -synuclein-positive participants in ADNI compared to BioFINDER-2, including a greater proportion of participants with cognitive impairment and an older population. Patients with advanced MCI or

dementia are also more likely to start showing slower accumulation of A β pathology, which might also explain part of the different longitudinal trajectories. Further, in BioFINDER-2, patients with dementia do not undergo A β PET. Another limitation is the binary measure of α -synuclein but α -synuclein SAAs development has not yet reached the stage of providing accurate continuous α -synuclein seed levels. More quantitative measures will be important to evaluate the links between continuous levels of the different pathologies in the future. For instance, the time to reach the positivity threshold in the SAA (kinetic parameter lag phase) is a promising marker currently being investigated.^{35,36}

The current results also have potential immediate and future clinical implications. First, our results suggest that patients showing cognitive decline and A β positivity with limited associated tau pathology are at significant risk of having AD and Lewy body copathology. The results are also relevant in light of the recently approved anti-amyloid therapies: we can speculate that, given the association between A β and α -synuclein, removing A β could have a downstream effect of lowering α -synuclein pathology. Of course the opposite could also be true, that is, facilitating removal of α -synuclein would also lower A β levels, and it would be an important pathway to test when such therapies emerge.

Overall, along the AD spectrum, we found evidence for concomitant α -synuclein and A β and interaction between the two pathologies in two large cohorts. Future studies should investigate if there are potential additive or synergistic effects of abnormal α -synuclein and A β accumulation in vivo and the molecular mechanisms that are at play.

ACKNOWLEDGMENTS

The authors would like to acknowledge all the BioFINDER team members as well as participants in the study and their family members for their dedication. APB is supported by a postdoctoral fellowship from the Fonds de recherche en Santé Québec (298314, APB). The BioFINDER study was supported by the National Institute on Aging (R01AG083740), European Research Council (ADG-101096455), Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775, 2021-02219, 2018-02052), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907, AF-980832, AF-993465, AF-939981), Swedish Brain Foundation (FO2021-0293, FO2023-0163), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, WASP and DDLS Joint call for research projects (WASP/DDLS22-066), EU Joint Programme Neurodegenerative Diseases (2019-03401), Rönström Family Foundation (FRS-0003), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), and Swedish federal government under the ALF agreement (2022-Projekt0080, 2022-Projekt0107). The precursor of ¹⁸F-flutemetamol was sponsored by GE Healthcare. The precursor of ¹⁸F-RO948 was provided by Roche. The funding sources had no role in the design and conduct of the study; in the collection, analysis, interpretation of the data; or in the preparation,

review, or approval of the manuscript. The part of data collection performed at the Laboratory of Neuropathology, Bologna Italy, was supported by the grant Ricerca Finalizzata-2021-12374386, funded by the Italian Ministero della Salute. Part of data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-20012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; BristolMyers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; MesoScale Diagnostics, LLC; NeuroRxResearch; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

CONFLICT OF INTEREST STATEMENT

OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. RS has received a speaker fee from Roche. SP has acquired research support (for the institution) from ki elements / ADDF. In the past 2 years, he has received consultancy/speaker fees from BioArctic, Biogen, Lilly, and Roche. The remaining authors declare no competing interests. Author disclosures are available in the [supporting information](#).

CONSENT STATEMENT

All participants provided written informed consent.

ORCID

Alexa Pichet Binette  <https://orcid.org/0000-0001-5218-3337>

REFERENCES

- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. *Nature*. 1997;388(6645):839-840. doi:10.1038/42166
- Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. *Lancet Neurol*. 2024;23(2):178-190. doi:10.1016/S1474-4422(23)00405-2
- Spina S, La Joie R, Petersen C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. *Brain*. 2021;144(7):2186-2198. doi:10.1093/brain/awab099
- Robinson JL, Richardson H, Xie SX, et al. The development and convergence of co-pathologies in Alzheimer's disease. *Brain*. 2021;144(3):953-962. doi:10.1093/brain/awaa438
- Robinson JL, Xie SX, Baer DR, et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. *Brain*. 2023;146(6):2557-2569. doi:10.1093/brain/awad059
- Ichimata S, Yoshida K, Li J, Rogaeva E, Lang AE, Kovacs GG. The molecular spectrum of amyloid-beta (Abeta) in neurodegenerative diseases beyond Alzheimer's disease. *Brain Pathol*. 2024;34(1):e13210. doi:10.1111/bpa.13210
- Toledo JB, Gopal P, Raible K, et al. Pathological alpha-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. *Acta Neuropathol*. 2016;131(3):393-409. doi:10.1007/s00401-015-1526-9
- Visanji NP, Lang AE, Kovacs GG. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. *Transl Neurodegener*. 2019;8:28. doi:10.1186/s40035-019-0172-x
- Bassil F, Brown HJ, Pattabhiraman S, et al. Amyloid-Beta (Abeta) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with abeta pathology. *Neuron*. 2020;105(2):260-275. doi:10.1016/j.neuron.2019.10.010
- Candelise N, Baiardi S, Franceschini A, Rossi M, Parchi P. Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids. *Acta Neuropathol Commun*. 2020;8(1):117. doi:10.1186/s40478-020-00990-x
- Palmqvist S, Rossi M, Hall S, et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. *Nat Med*. 2023. doi:10.1038/s41591-023-02450-0
- Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. *JAMA*. 2020;324(8):772-781. doi:10.1001/jama.2020.12134
- Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology*. 2010;74(3):201-209. doi:10.1212/WNL.0b013e3181cb3e25
- Groverman BR, Orru CD, Hughson AG, et al. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. *Acta Neuropathol Commun*. 2018;6(1):7. doi:10.1186/s40478-018-0508-2
- Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. *Acta Neuropathol*. 2020;140(1):49-62. doi:10.1007/s00401-020-02160-8
- Tosun D, Hausle Z, Iwaki H, et al. A cross-sectional study of alpha-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: prevalence and associations with Alzheimer's disease biomarkers and cognitive function. *Alzheimers Dement*. 2024. doi:10.1002/alz.13858
- Arnold MR, Coughlin DG, Brumbach BH, et al. alpha-synuclein seed amplification in csf and brain from patients with different brain distributions of pathological alpha-synuclein in the context of co-pathology and non-LBD diagnoses. *Ann Neurol*. 2022;92(4):650-662. doi:10.1002/ana.26453
- Bentivenga GM, Mammana A, Baiardi S, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathol-

- ogy burden. *Acta Neuropathol.* 2024;147(1):18. doi:[10.1007/s00401-023-02663-0](https://doi.org/10.1007/s00401-023-02663-0)
19. Russo MJ, Orru CD, Concha-Marambio L, et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. *Acta Neuropathol Commun.* 2021;9(1):179. doi:[10.1186/s40478-021-01282-8](https://doi.org/10.1186/s40478-021-01282-8)
 20. Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. *JAMA Neurol.* 2020. doi:[10.1001/jamaneurol.2020.0989](https://doi.org/10.1001/jamaneurol.2020.0989)
 21. Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. *Nat Med.* 2022;28(11):2381-2387. doi:[10.1038/s41591-022-02049-x](https://doi.org/10.1038/s41591-022-02049-x)
 22. Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimers Dement.* 2017;13(3):205-216. doi:[10.1016/j.jalz.2016.08.005](https://doi.org/10.1016/j.jalz.2016.08.005)
 23. Blennow K, Shaw LM, Stomrud E, et al. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβeta(1-42), pTau and tTau CSF immunoassays. *Sci Rep.* 2019;9(1):19024. doi:[10.1038/s41598-019-54204-z](https://doi.org/10.1038/s41598-019-54204-z)
 24. Pichet Binette A, Franzmeier N, Spotorno N, et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. *Nat Commun.* 2022;13(1):6635. doi:[10.1038/s41467-022-34129-4](https://doi.org/10.1038/s41467-022-34129-4)
 25. Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimers Dement.* 2018;14(11):1470-1481. doi:[10.1016/j.jalz.2018.01.010](https://doi.org/10.1016/j.jalz.2018.01.010)
 26. Hansson O, Rutz S, Zetterberg H, et al. Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. *Alzheimers Dement (Amst).* 2020;12(1):e12137. doi:[10.1002/dad2.12137](https://doi.org/10.1002/dad2.12137)
 27. Hansson O, Batrla R, Brix B, et al. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau. *Alzheimers Dement.* 2021;17(9):1575-1582. doi:[10.1002/alz.12316](https://doi.org/10.1002/alz.12316)
 28. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. *Brain Pathol.* 2000;10(3):378-384. doi:[10.1111/j.1750-3639.2000.tb00269.x](https://doi.org/10.1111/j.1750-3639.2000.tb00269.x)
 29. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution—a pilot study. *Acta Neuropathol.* 2003;106(3):191-201. doi:[10.1007/s00401-003-0725-y](https://doi.org/10.1007/s00401-003-0725-y)
 30. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *Am J Pathol.* 1998;153(5):1365-1370. doi:[10.1016/s0002-9440\(10\)65722-7](https://doi.org/10.1016/s0002-9440(10)65722-7)
 31. Rosenberg CK, Pericak-Vance MA, Saunders AM, Gilbert JR, Gaskell PC, Hulette CM. Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. *Acta Neuropathol.* 2000;100(2):145-152. doi:[10.1007/s004019900155](https://doi.org/10.1007/s004019900155)
 32. Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. *Acta Neuropathol.* 2017;134(2):187-205. doi:[10.1007/s00401-017-1709-7](https://doi.org/10.1007/s00401-017-1709-7)
 33. Kotzbauer PT, Trojanowski JQ, Lee VM. Lewy body pathology in Alzheimer's disease. *J Mol Neurosci.* 2001;17(2):225-232. doi:[10.1385/jmn.17.2.225](https://doi.org/10.1385/jmn.17.2.225)
 34. Khan SS, LaCroix M, Boyle G, et al. Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. *Acta Neuropathol.* 2018;136(4):589-605. doi:[10.1007/s00401-018-1886-z](https://doi.org/10.1007/s00401-018-1886-z)
 35. Brockmann K, Lerche S, Baiardi S, et al. CSF alpha-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson's disease. *NPJ Parkinsons Dis.* 2024;10(1):24. doi:[10.1038/s41531-023-00627-5](https://doi.org/10.1038/s41531-023-00627-5)
 36. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol.* 2011;10(9):819-828. doi:[10.1016/S1474-4422\(11\)70072-2](https://doi.org/10.1016/S1474-4422(11)70072-2)

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Pichet Binette A, Mammana A, Wisse L, et al. Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo. *Alzheimer's Dement.* 2024;1-11.
<https://doi.org/10.1002/alz.14225>